Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H12NO3.Na |
Molecular Weight | 277.2504 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].NC1=C(C=CC=C1CC([O-])=O)C(=O)C2=CC=CC=C2
InChI
InChIKey=MJAQSCHBMPGJES-UHFFFAOYSA-M
InChI=1S/C15H13NO3.Na/c16-14-11(9-13(17)18)7-4-8-12(14)15(19)10-5-2-1-3-6-10;/h1-8H,9,16H2,(H,17,18);/q;+1/p-1
DescriptionCurator's Comment: Description was created based on several sources, including https://link.springer.com/article/10.1007/BF03299088 | http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=35377 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000MedR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021862lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/10850857
Curator's Comment: Description was created based on several sources, including https://link.springer.com/article/10.1007/BF03299088 | http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=35377 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203491Orig1s000MedR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021862lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/10850857
Amfenac (AHR 5850) is a non-steroidal anti-inflammatory compound possessing antipyretic and analgesic properties. It is an inhibitor of cyclooxygenases. Amfenac sodium has been on the Japanese market since 1986 (as FENAZOX®, Meiji) in an oral dosage form (50 mg, four-times-daily) indicated for the treatment of pain and inflammation associated with rheumatoid and osteoarthritis and low back pain, as well as the treatment of pain and inflammation following surgery, injury or tooth extraction. Amfenac is an active moiety of nepafenac (amfenac amide), the prodrug has very weak cyclooxygenase inhibitory activity whereas amfenac exhibits more potent cyclooxygenase activity. Nepafenac at a concentration of 0.1% (NEVANAC) was approved for marketing in the US in 2005. Nepafenac is also approved for marketing in the European Union(EU) and Japan as well as over 60 other countries for the treatment of postoperative pain and inflammation associated with cataract surgery.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL221 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D05143 |
64.3 µM [IC50] | ||
Target ID: CHEMBL230 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D05143 |
0.15 µM [IC50] | ||
Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10850857 |
0.25 µM [IC50] | ||
Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10850857 |
0.15 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | NEVANAC Approved UseNEVANAC ophthalmic suspension is a nonsteroidal, antiinflammatory prodrug indicated for the treatment of pain and
inflammation associated with cataract surgery Launch Date1.12432316E12 |
|||
Primary | FENAZOX Approved UseFENAZOX CAPSULES (Amfenac sodium hydrate) is usually used to relieve inflammation and pain in chronic rheumatoid arthritis, osteoarthritis, low back pain, shoulder periarthritis, cervico-omo-brachial syndrome, temporomandibular joint disease, post-operative state, post-traumatic state or post-odontectomy state. Launch Date5.04835211E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
205.3 ng/mL |
1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered: |
NEPAFENAC aqueous humor | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.847 ng/mL |
1 drop 1 times / day steady-state, ocular dose: 1 drop route of administration: Ocular experiment type: STEADY-STATE co-administered: |
NEPAFENAC unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
331.1 ng × h/mL |
1 drop single, ocular dose: 1 drop route of administration: Ocular experiment type: SINGLE co-administered: |
NEPAFENAC aqueous humor | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1 drop 1 times / day multiple, topical Recommended Dose: 1 drop, 1 times / day Route: topical Route: multiple Dose: 1 drop, 1 times / day Sources: Page: p.209 |
unhealthy, 68.7+/- 9.08 n = 817 Health Status: unhealthy Condition: Pain and inflammation associated with cataract surgery Age Group: 68.7+/- 9.08 Sex: M+F Population Size: 817 Sources: Page: p.209 |
Disc. AE: Hypersensitivity... AEs leading to discontinuation/dose reduction: Hypersensitivity (0.12%) Sources: Page: p.209 |
1 drop 1 times / day multiple, topical Recommended Dose: 1 drop, 1 times / day Route: topical Route: multiple Dose: 1 drop, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain and inflammation associated with cataract surgery Sources: Page: p.1 |
Disc. AE: Bleeding, Healing delayed... AEs leading to discontinuation/dose reduction: Bleeding Sources: Page: p.1Healing delayed Corneal disorder (NOS) Keratitis |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypersensitivity | 0.12% Disc. AE |
1 drop 1 times / day multiple, topical Recommended Dose: 1 drop, 1 times / day Route: topical Route: multiple Dose: 1 drop, 1 times / day Sources: Page: p.209 |
unhealthy, 68.7+/- 9.08 n = 817 Health Status: unhealthy Condition: Pain and inflammation associated with cataract surgery Age Group: 68.7+/- 9.08 Sex: M+F Population Size: 817 Sources: Page: p.209 |
Bleeding | Disc. AE | 1 drop 1 times / day multiple, topical Recommended Dose: 1 drop, 1 times / day Route: topical Route: multiple Dose: 1 drop, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain and inflammation associated with cataract surgery Sources: Page: p.1 |
Corneal disorder (NOS) | Disc. AE | 1 drop 1 times / day multiple, topical Recommended Dose: 1 drop, 1 times / day Route: topical Route: multiple Dose: 1 drop, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain and inflammation associated with cataract surgery Sources: Page: p.1 |
Healing delayed | Disc. AE | 1 drop 1 times / day multiple, topical Recommended Dose: 1 drop, 1 times / day Route: topical Route: multiple Dose: 1 drop, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain and inflammation associated with cataract surgery Sources: Page: p.1 |
Keratitis | Disc. AE | 1 drop 1 times / day multiple, topical Recommended Dose: 1 drop, 1 times / day Route: topical Route: multiple Dose: 1 drop, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Pain and inflammation associated with cataract surgery Sources: Page: p.1 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 14.0 |
inconclusive | |||
Page: 14.0 |
inconclusive | |||
Page: 8, 14 |
no | |||
Page: 8, 14 |
no | |||
Page: 8, 14 |
no | |||
Page: 8, 14 |
no | |||
Page: 8, 14 |
no | |||
Page: 8, 14 |
no | |||
Page: 8, 14 |
no | |||
Page: 8, 14 |
no | |||
Page: 8, 14 |
no | |||
Page: 8, 14 |
no | |||
Page: 8, 14 |
no | |||
Page: 8, 14 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 14.0 |
inconclusive | |||
Page: 14.0 |
inconclusive | |||
Page: 14.0 |
inconclusive | |||
Page: 14.0 |
likely | |||
Page: 14.0 |
likely |
PubMed
Title | Date | PubMed |
---|---|---|
Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid. | 1979 Sep |
|
Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. | 2000 Aug |
|
Pharmacokinetics of topical ocular drug delivery: potential uses for the treatment of diseases of the posterior segment and beyond. | 2003 Jun |
|
Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. | 2003 Oct |
|
New drugs 06, part II. | 2006 Aug |
|
New drugs: ramelteon, tipranavir, nepafenac, and deferasirox. | 2006 Jan-Feb |
|
Double-masked study of the effects of nepafenac 0.1% and ketorolac 0.4% on corneal epithelial wound healing and pain after photorefractive keratectomy. | 2007 Jul-Aug |
|
Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. | 2007 Nov |
|
The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production. | 2007 Nov 27 |
|
Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK). | 2007 Nov-Dec |
|
In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. | 2007 Sep |
|
The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. | 2007 Sep |
|
Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation. | 2008 Apr |
|
Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery. | 2008 Dec |
|
Topical ocular delivery of NSAIDs. | 2008 Jun |
|
Corneal melting after use of nepafenac in a patient with chronic cystoid macular edema after cataract surgery. | 2008 Mar |
|
Ketorolac versus nepafenac in cataract surgery. | 2008 Mar |
|
Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients. | 2008 Nov-Dec |
|
Effect of nepafenac sodium 0.1% on delayed corneal epithelial healing and haze after photorefractive keratectomy: retrospective comparative study. | 2008 Sep |
|
Intracameral dexamethasone reduces inflammation on the first postoperative day after cataract surgery in eyes with and without glaucoma. | 2009 |
|
Gateways to clinical trials. | 2009 Apr |
|
Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema. | 2010 Jan |
|
Topical nepafenac for treatment of exudative age-related macular degeneration. | 2010 Mar |
|
Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: a randomized trial. | 2012 Jul |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/nepafenac.html
One drop of Nepafenac ophthalmic suspension, 0.3% should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10850857
Nepafenac exhibited only weak COX-1 inhibitory activity (IC50 = 64.3 uM). However, amfenac, an active metabolite of nepafenac, was a potent inhibitor of COX-1 (IC50 = 0.25 uM) and COX-2 activity (IC50 = 0.15 uM).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID8048658
Created by
admin on Fri Dec 15 15:23:47 UTC 2023 , Edited by admin on Fri Dec 15 15:23:47 UTC 2023
|
PRIMARY | |||
|
61941-56-8
Created by
admin on Fri Dec 15 15:23:47 UTC 2023 , Edited by admin on Fri Dec 15 15:23:47 UTC 2023
|
PRIMARY | |||
|
C20288EWAG
Created by
admin on Fri Dec 15 15:23:47 UTC 2023 , Edited by admin on Fri Dec 15 15:23:47 UTC 2023
|
PRIMARY | |||
|
23665728
Created by
admin on Fri Dec 15 15:23:47 UTC 2023 , Edited by admin on Fri Dec 15 15:23:47 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD